Stock Screener App

Frei -

Installieren

Drug Manufacturers - Specialty & Generic

473.66

0.52% -2.47

United Therapeutics Corp (UTHR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt UTHR? Forum Prognose Aktiensplit

United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten

MidWestOne Financial Group Inc. Raises Holdings in United Therapeutics Corporation $UTHR - MarketBeat

Can United Therapeutics Corporation navigate macro headwindsTrade Risk Summary & High Return Stock Watch Alerts - mfd.ru

Can United Therapeutics Corporation be recession proof2025 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn

LSV Asset Management Sells 177,913 Shares of United Therapeutics Corporation $UTHR - MarketBeat

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2025 Financial Results Before the Market Opens on Wednesday, February 25, 2026 - Stock Titan

United Therapeutics (NASDAQ:UTHR) COO Sells $10,679,625.00 in Stock - MarketBeat

United Therapeutics Nears Key Data Milestone With Completed TETON-1 IPF Trial - TipRanks

United Therapeutics Corporation $UTHR Shares Sold by Ashton Thomas Private Wealth LLC - MarketBeat

BI Asset Management Fondsmaeglerselskab A S Cuts Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat

Assessing United Therapeutics (UTHR) Valuation After Positive MiroliverELAP Phase 1 Safety And Survival Data - simplywall.st

Aug Fed Impact: Will United Therapeutics Corporation benefit from government policyJuly 2025 Rallies & Risk Controlled Daily Plans - baoquankhu1.vn

Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus

Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock - MarketBeat

United Therapeutics Corporation $UTHR Shares Purchased by AE Wealth Management LLC - MarketBeat

Mediolanum International Funds Ltd Sells 4,275 Shares of United Therapeutics Corporation $UTHR - MarketBeat

United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

United Therapeutics Corporation (UTHR) Stock Analysis: Exploring A 13% Upside Potential - DirectorsTalk Interviews

Bank of New York Mellon Corp Sells 11,016 Shares of United Therapeutics Corporation $UTHR - MarketBeat

Summit Global Investments Sells 3,327 Shares of United Therapeutics Corporation $UTHR - MarketBeat

A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack - Yahoo Finance

Therapeutics Stocks Q3 Highlights: United Therapeutics (NASDAQ:UTHR) - Finviz

Mutual of America Capital Management LLC Acquires 4,036 Shares of United Therapeutics Corporation $UTHR - MarketBeat

Mitsubishi UFJ Trust & Banking Corp Sells 13,401 Shares of United Therapeutics Corporation $UTHR - MarketBeat

Strs Ohio Has $4.22 Million Stake in United Therapeutics Corporation $UTHR - MarketBeat

What's Going On With United Therapeutics Stock Monday?United Therapeutics (NASDAQ:UTHR) - Benzinga

United Therapeutics reports positive phase 1 results for bioengineered liver By Investing.com - Investing.com Canada

How Investors May Respond To United Therapeutics (UTHR) Positive Early Data For Bioengineered Liver Support Device - Yahoo Finance

United Therapeutics reports positive phase 1 results for bioengineered liver - Investing.com

Retirement Systems of Alabama Sells 18,709 Shares of United Therapeutics Corporation $UTHR - MarketBeat

World’s first FDA-cleared bioengineered liver trial meets survival goal - Stock Titan

The Best Pharma Stock I’ve Ever Seen - Nanalyze

United Therapeutics appoints biomedical research leader to board By Investing.com - Investing.com Nigeria

United Therapeutics Appoints Kevin J. Tracey To Board - citybiz

United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to Board of Directors, Effective January 21, 2026 - marketscreener.com

United Therapeutics appoints biomedical research leader to board - Investing.com

United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors - United Therapeutics Investor Relations

Element Squared LLC Buys 5,027 Shares of United Therapeutics Corp (UTHR) - GuruFocus

Marquette Asset Management, LLC Buys 1 Shares of United Therapeutics Corp (UTHR) - GuruFocus

United Therapeutics Corporation (UTHR): A Bull Case Theory - Finviz

Polaris Capital Management LLC Sells 5,600 Shares of United Therapeutics Corporation $UTHR - MarketBeat

Reassessing United Therapeutics (UTHR) Valuation After Strong 1 Year Share Price Performance - Yahoo Finance

United Therapeutics COO sells $10.7 million in UTHR stock - Investing.com

United Therapeutics’ Phase 3 Ralinepag Trial Reaches Completion, Setting Up a Key Catalyst in Pulmonary Arterial Hypertension - TipRanks

United Therapeutics Corporation $UTHR Shares Sold by State of Alaska Department of Revenue - MarketBeat

SG Americas Securities LLC Purchases 7,483 Shares of United Therapeutics Corporation $UTHR - MarketBeat

United Therapeutics Corporation $UTHR Position Decreased by Nepsis Inc. - MarketBeat

How United Therapeutics Corporation (UTH) stock expands through international marketsTreasury Yields & Verified Swing Trading Watchlists - Улправда

Is United Therapeutics Corporation stock a good choice for value investorsJuly 2025 Recap & AI Enhanced Execution Alerts - Улправда

MannKind Provides Business Updates and 2026 Growth Drivers - Benzinga

Robeco Institutional Asset Management B.V. Has $38.19 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat

United Therapeutics (NASDAQ:UTHR) COO Sells $7,127,932.50 in Stock - MarketBeat

Director Jan Malcolm Sells Shares of United Therapeutics Corp - GuruFocus

United Therapeutics (UTHR): UBS Raises Price Target, Maintains B - GuruFocus

Is United Therapeutics Corporation's (NASDAQ:UTHR) Recent Performance Tethered To Its Attractive Financial Prospects? - Yahoo Finance

United Therapeutics (NASDAQ:UTHR) Director Christopher Causey Sells 1,000 Shares - MarketBeat

United Therapeutics Corporation (UTHR) Stock Analysis: A Healthcare Giant with Strong Growth Potential and Robust Analyst Support - DirectorsTalk Interviews

Biotech developing organ transplant tech steps onto J.P. Morgan stage - Stock Titan

VTRS

$15.77

0.13%

RGC

$31.22

7.58%

ELAN

$25.13

1.37%

NBIX

$124.12

0.83%

RDY

$14.14

1.19%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters